EUVIMEDEUVIMED entdecken
Open Access

The IsletTester Mouse: An Immunodeficient Model With Stable Hyperglycemia for the Study of Human Islets

Eric L Waite iD, Mark Tigue, Ming Yu, Deeksha Lahori, Kai Kelly, Catherine Lee May, Ali Naji, Jeffrey Roman, Nicolai Doliba, Dana Avrahami, Kim-Vy Nguyen-Ngoc, Maike Sander und 2 weitere

Diabetes · 2025

DOI: 10.2337/db23-0887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Eric L Waite und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Hyperglycemia, Islets of Langerhans Transplantation, Islets of Langerhans, Insulin-Secreting Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Israel Science Foundation, United States-Israel Binational Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gold standard for assessing the function of human islets or β-like cells derived from stem cells involves their engraftment under the kidney capsule of hyperglycemic, immunodeficient mice. Current models, such as streptozotocin treatment of severely immunodeficient mice or the NRG-Akita strain, are limited due to unstable and variable hyperglycemia and/or high morbidity. To address these limitations, we developed the IsletTester mouse via CRISPR/Cas9-mediated gene editing of glucokinase (Gck), the glucose sensor of the β-cells, directly in NSG zygotes. IsletTester mice are heterozygous for an Arg345→stop mutation in Gck and present with stable random hyperglycemia (∼250 mg/dL [14 mmol/L]), normal lifespan, and fertility. We demonstrate the utility of this model through functional engraftment of both human islets and human embryonic stem cell–derived β-like cells. The IsletTester mouse will enable the study of human islet biology over time and under different physiological conditions and can provide a useful preclinical platform to determine the functionality of stem cell–derived islet products. Article Highlights Current mouse models for assessing islet function in vivo are limited due to unstable and variable hyperglycemia and/or high morbidity. We derived the IsletTester mouse to address these limitations. Leveraging a previously characterized glucokinase mutation and CRISPR/Cas9 technology, we successfully developed a moderately hyperglycemic and immunodeficient mouse model for the in vivo assessment of islet function. Our IsletTester mouse has stable, moderate hyperglycemia that can be corrected with primary human islets or stem cell–derived insulin-producing cells. The IsletTester mouse provides a reliable, easy-to-use platform for the preclinical assessment of stem cell–derived islet products or islet-targeted drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperglycemiaIslets of Langerhans TransplantationIslets of LangerhansInsulin-Secreting CellsAnimalsHumansMiceDisease Models, AnimalGlucokinaseCRISPR-Cas SystemsGene EditingMice, Inbred NODFemale

Substanzen

Glucokinase

Autor:innen und Institutionen

  • Institute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA.
  • Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
  • Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada (IMRIC), Hebrew University-Hadassah Medical School, Jerusalem, Israel.
  • Departments of Pediatrics and Cellular and Molecular Medicine, Pediatric Diabetes Research Center, University of California, San Diego, La Jolla, CA.

ORCID-Profile: Eric L Waite, Benjamin Glaser, Klaus H Kaestner

Förderung

  • NIDDK NIH HHS
  • Israel Science Foundation
  • United States-Israel Binational Science Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Waite, E. L., Tigue, M., Yu, M., Lahori, D., Kelly, K., May, C. L., Naji, A., Roman, J., Doliba, N., Avrahami, D., Nguyen-Ngoc, K. V., Sander, M., Glaser, B., & Kaestner, K. H. (2025). The IsletTester Mouse: An Immunodeficient Model With Stable Hyperglycemia for the Study of Human Islets. Diabetes. https://doi.org/10.2337/db23-0887

Vancouver

Waite EL, Tigue M, Yu M, Lahori D, Kelly K, May CL, et al. The IsletTester Mouse: An Immunodeficient Model With Stable Hyperglycemia for the Study of Human Islets. Diabetes. 2025. doi:10.2337/db23-0887

BibTeX
@article{Waite2025,
  author = {Waite, Eric L and Tigue, Mark and Yu, Ming and Lahori, Deeksha and Kelly, Kai and May, Catherine Lee and Naji, Ali and Roman, Jeffrey and Doliba, Nicolai and Avrahami, Dana and Nguyen-Ngoc, Kim-Vy and Sander, Maike and Glaser, Benjamin and Kaestner, Klaus H},
  title = {The IsletTester Mouse: An Immunodeficient Model With Stable Hyperglycemia for the Study of Human Islets},
  journal = {Diabetes},
  year = {2025},
  doi = {10.2337/db23-0887}
}
Kostenlos starten →